About Neurofibromatosis Type 2
Neurofibromatosis type 2 (NF2) is caused by mutations in the NF2 tumor suppressor gene encoding merlin (schwannomin), a cytoskeletal protein. The hallmark is bilateral vestibular schwannomas causing progressive hearing loss, tinnitus, and balance problems. Patients also develop meningiomas, ependymomas, and other schwannomas throughout the nervous system. Bevacizumab has shown benefit for vestibular schwannoma growth; FAK inhibitors and MEK inhibitors are in active trials.
Common Clinical Features
Clinical Trial Eligibility Tips
What to know before applying to Neurofibromatosis Type 2 trials.
Tumor growth rate on serial MRI (typically requiring 2 scans 6 months apart) is a standard eligibility criterion
Hearing assessment (audiogram and word recognition scores) at baseline is required — hearing preservation is a key trial endpoint
Bevacizumab treatment history and response must be documented for anti-angiogenic and alternative therapy trials
NF2 severity scale (Manchester) and Karnofsky performance status are used for trial stratification
Patient Resources
Find recruiting Neurofibromatosis Type 2 trials
Search 500,000+ studies from ClinicalTrials.gov, filtered for Neurofibromatosis Type 2. Updated daily.